drugset / Trial / NCT07332936

Tobradex as Intracanal Medicament

NCT07332936

Completed 43 enrolled Umm Al-Qura University
Non-randomizedParallel-groupSingle-blindTreatment

Summary

The goal of this prospective clinical study was to evaluate and compare the short-term effects of two intracanal medicaments-calcium hydroxide and a tobramycin-dexamethasone combination (Tobradex)-on postoperative pain following emergency root canal treatment in adult patients with symptomatic irreversible pulpitis. The main question it aimed to answer was: Does Tobradex reduce postoperative endodontic pain more effectively than calcium hydroxide within the first 48 hours after emergency root canal treatment? Adult patients presenting with acute dental pain and already receiving emergency root canal therapy as part of their routine clinical care were included. After canal debridement, patients received either calcium hydroxide or Tobradex as an intracanal medicament based on availability at the time of treatment. Participants reported their pain intensity using a numeric rating scale before treatment and again at 24 and 48 hours following the procedure. Pain outcomes were compared between groups, and the influence of demographic factors such as age and gender was also explored.

Timeline

Start
2023-07-01
Primary completion
2024-06-30
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Calcium Hydroxide Other / unclassified Other
Subject Dexamethasone Small molecule Other
Subject Tobramycin Small molecule Other